TITLE

WEEK IN REVIEW

PUB. DATE
October 2009
SOURCE
BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents financings and deals of pharmaceutical companies. Adventrx Pharmaceuticals Inc. received a gross income of 11.3 million dollars from its registered direct offering of stock and warrants. Allos Therapeutics Inc. obtained on its disclosed public stock offering a net income of 93 million dollars. Onyx Pharmaceuticals Inc. acquired the cancer company Proteolix Inc. in an 851 million dollar worth deal.
ACCESSION #
44860032

 

Related Articles

  • Proteolix's Proteasome Inhibitor Drives Onyx Deal.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p3 

    The article reports that Emeryville, California-based Onyx Pharmaceuticals Inc. has agreed to acquire Proteolix Inc. of South Francisco, California in a potential deal worth 851 million dollars. It notes that the acquisition of Proteolix Inc. aims to help Onyx expand its pipeline to bridge the...

  • Onyx Pharmaceuticals to acquire Proteolix.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p33 

    The article reports on the signed definitive agreement to acquire biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. It notes that Proteolix is set to be paid 276 million dollars upon finalization of the transaction in the fourth quarter of 2009. It mentions that Proteolix is...

  • Onyx Pharmaceuticals completes acquisition of Proteolix.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p26 

    The article reports on the acquisition of the biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. for the development of medical therapies against hematological tumors. According to Onyx chief executive officer (CEO), Anthony Coles, the acquisition places the firm as a...

  • Onyx's Proteolix Grab: Pipeline Backfill - and Maybe MM Ticket. Osborne, Randy // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p3 

    The article reports on the possible approval of carfilzomib, which is said to have driven the 851 million-dollar buyout of Proteolix Inc. by Onyx Pharmaceuticals Inc. It states that the proteasome inhibitor is similar to the Velcade drug. It notes that Onyx considers the deal with Proteolix as a...

  • For $339M Onyx Carves Out Carfilzomib Japanese Rights. Morrison, Trista // BioWorld Today;9/9/2010, Vol. 21 Issue 174, p1 

    The article focuses on the acquisition of Proteolix Inc. by Onyx Pharmaceuticals Inc. Under the deal, Onyx Pharmaceuticals Inc., which will market carfilzomib by itself in the U.S. and Europe, will take 59 million U.S. dollars up front, 280 million U.S. dollars in potential milestones and...

  • Proteolix's Proteasome Inhibitor Drives Much-Awaited Onyx Deal. Boggs, Jennifer // BioWorld Today;10/13/2009, Vol. 20 Issue 197, p1 

    The article reports on the acquisition of Proteolix Inc. by Onyx Pharmaceuticals Inc. The acquisition was centered on carfilzomib, which is a proteasome inhibitor for multiple myeloma. Carfilzomib is aimed to bridge the gap between an approved cancer drug, Nexavar (sorafenib), and two...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;8/2/2010, Vol. 18 Issue 29, p4 

    The article presents news brief related to the drug industry. Allos Therapeutics Inc. reports that its lung-cancer drug Folotyn increased survival of patients, however, the lower sales raised concern about the marketing opportunity. A study revealed that prostate cancer vaccine Provenge...

  • Biotech Mergers And Acquisitions: Sept. 1, 2012 - March 28, 2013#.  // BioWorld Insight;4/1/2013, Vol. 21 Issue 14, p7 

    A chart is presented that lists mergers and acquisitions in the biotechnology industry from September 1, 2012 to March 28, 2013 including Allos Therapeutics Inc. and Spectrum Pharmaceuticals Inc., CNS Therapeutics Inc. and Mallinckrodt, and DeCode Genetics and Amgen Inc.

  • Today's Transactions: Spectrum Subsumes Allos.  // Mergers & Acquisitions Report;4/9/2012, Vol. 25 Issue 15, p17 

    The article reports on the decision of Spectrum Pharmaceuticals Inc. to acquire biopharmaceutical firm Allos Therapeutics Inc. for about 206 million U.S. dollars, or 1.82 U.S. dollars per share in cash.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics